Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries

Roberto José Pessoa de Magalhães FilhoEdvan de Queiroz CrusoéEloísa RivaWillen BujanGuilhermo ConteJuan Ramon Navarro CabreraDiana Katerine GarciaGuilhermo Quintero VegaJosé Antonio Rosendo MacíasJose Willian Oliveros Alvear2026-03-222026-03-22201810.1016/j.clml.2018.08.005https://doi.org/10.1016/j.clml.2018.08.005https://andeanlibrary.org/handle/123456789/44863Citaciones: 41enMultiple myelomaBortezomibLenalidomideThalidomideMedicineMelphalanTransplantationFamily medicineOncologyInternal medicineAnalysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countriesarticle